Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions for reducing incidence of necrotizing enterocolitis

A technology for enterocolitis and composition, applied in reducing the incidence of necrotizing enterocolitis, preparation for gastrointestinal tract administration and preparation of the gastrointestinal tract administration composition, first field

Inactive Publication Date: 2005-05-11
ABBOTT LAB INC +1
View PDF10 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, there may also be a protective effect on internal organs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment I

[0078] Egg yolk phospholipids were purchased from Pfanstiehl, Inc. (Waukegan, IL, catalog number: P-123) and used in the following examples. The fatty acid and cholesterol profiles of the egg phospholipids are listed in Table I. The total number of all n-3 and all n-6 "long-chain" PUFAs is also given.

[0079] Table I: Fatty acid profile and cholesterol content in egg yolk lecithin

[0080] Fatty acid gm / 100gm sample

[0081] C14:0 0.08

[0082] C16:0 18.83

[0083] C16:1n-7 0.82

[0084] C16:4 0.21

[0085] C18:0 6.72

[0086] C18:1n-9 17.36

[0087] C18:2n-6 9.8

[0088] C20:1n-9 0.11

[0089] C20:2n-6 0.24

[0090] C20:3n-6 0.3

[0091] C20:4 n-6-arachidonic acid 4.93

[0092] C22:0 0.07

[0093] C22:4 n-6 0.3

[0094] C22:5n-6 1.45

[0095] C22:5n-3 0.09

[0096] C22:6 n-3 docosahexaenoic acid 1.24

[0097] Cholesterol <0.05

[0098] Total LCPUFA n-6 7.22

[0099] Total LCPUFA n-3 1.33

[0100] Those skilled in the art can understand: because the ki...

Embodiment II

[0102] In this example, "experimental" and "control" infant formulas were prepared with and without the egg phospholipids of Example I. The control composition is Similac Special Care  (Ross Products Division of Abott Laboratories, Columbus, Ohio), prepared by using the ingredients listed below, resulting in formulations having the compositions in Tables II-IV, wherein the ingredients are as follows:

[0103] Water (Kosher), Skim Milk, Hydrolyzed Corn Starch, Lactose, Fractionated Coconut Oil (Medium Chain Triglycerides), Whey Protein Concentrate, Soybean Oil, Coconut Oil, Calcium Phosphate Tribasic, Lemon Potassium Chloride, Sodium Citrate, Magnesium Chloride, Ascorbic Acid, Mono- and Diglycerides, Soy Lecithin, Calcium Carbonate, Carrageenan, Choline Chloride, Ferrous Sulfate, m-Inositol, Taurine, Niacinamide , L-carnitine, alpha-tocopheryl ethyl ester, zinc sulfate, calcium pantothenate, potassium chloride, copper sulfate, vitamin B 2 and vitamin A palmitate, thiamine hy...

Embodiment III

[0128] In this experiment, method variables were evaluated in order to reduce the sensory disadvantages associated with the application of egg phospholipids. Isolation of the egg phospholipids used in the present invention often leads to somewhat objectionable organoleptic properties of the egg phospholipids used in infant formulations. It can be further improved to provide a product which is not annoying to the baby and those who take care of the baby. This method of improving the final product is described below.

[0129] Prepare many nutritional preparations similar to Example II, the difference is: 6% by weight is the egg phospholipids of the fat mixture pretreated by various methods. Egg phospholipids were dispersed in a portion of the oil mixture described in Example II or in a portion of water. The oil dispersion is unacceptable and cannot be used even when heated to 95°C. Aqueous dispersions of the phospholipids can be heated relatively easily from room temperature ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Enteral formulas that contain long-chain polyunsaturated fatty acids (PUFAs), e.g., arachidonic acid (AA), and docosahexaenoic acid (DHA), essentially free of cholesterol, are described for use in methods for reducing the incidence of necrotizing enterocolitis. Compositions from egg yolk lipids are preferred as they contain omega-6 and omega-3 long chain PUFAs and are predominantly in a phosphtidylcholine form. This is believed to provide a synergetic effect.

Description

[0001] The present invention generally relates to enteral preparations containing long-chain polyunsaturated fatty acids (PUFAs) and methods for preparing the composition for enteral administration, and also relates to methods for reducing the incidence of necrotizing enterocolitis. More specifically, the present invention relates to a composition for gastrointestinal administration, which provides substantially cholesterol-free long-chain PUFAs arachidonic acid (AA) and docosahexaenoic acid (DHA), the combination can be obtained from egg yolk lipids. The long-chain PUFAs obtained from egg yolk mainly exist in the form of phospholipids. The preparation method of this composition provides better sensory and stability. The gastrointestinal tract administration route of the composition can reduce the incidence of necrotizing enterocolitis. Background of the invention [0002] Long-chain PUFAs in formulations or compositions for gastrointestinal administration have been describe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/14A61K31/215A61K31/685A61K9/10A61K31/66A23J7/00A23L1/30A61K31/201A61K31/202A61P1/00A61P43/00
CPCA61K31/202A61P1/00A61P43/00A61P9/10
Inventor S·E·卡尔森D·L·庞德M·B·蒙塔尔托M·H·多纳勒克J·D·本森D·A·博洛尔D·V·蒂奥达托
Owner ABBOTT LAB INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com